| Document |
Document Title |
|
WO/2023/273384A1 |
Provided in the present disclosure are a thermally activated delayed fluorescent material, an organic light-emitting device and a display apparatus. The energy level difference between a singlet energy level and a triplet energy level of...
|
|
WO/2023/276918A1 |
A compound represented by the following general formula is an excellent electronic barrier material. X represents a donor group; R1 to R6 represent substituents; and n1 to n6 represent integers greater than or equal to 0 and less than or...
|
|
WO/2023/277656A1 |
The present invention relates to a novel benzopyran derivative useful for preparing a drug for treating cancer, and more specifically, to a novel benzopyran derivative which is a micromolecule having a macrophage inhibitory effect and is...
|
|
WO/2023/279105A1 |
Provided herein are azetidine pyrimidine compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided ...
|
|
WO/2023/277313A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2023/277289A1 |
The present application provides: a heterocyclic compound; and an organic light-emitting device which comprises an organic layer containing the heterocyclic compound.
|
|
WO/2023/278729A1 |
The present application provides radioisotope-containing compounds that are, e.g., mGluR2 modulators. Methods of imaging brain of a patient, as well as methods of diagnosing and monitoring treatment of psychiatric or neurological disorde...
|
|
WO/2023/277446A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2023/279041A1 |
Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
|
|
WO/2023/277645A1 |
The invention relates to an organic molecule for the application in optoelectronic devices. According to the invention, the organic molecule has - a first chemical moiety comprising of a structure of formula I: Formula I and - one or two...
|
|
WO/2022/267945A1 |
The present invention belongs to the field of medicine and relates to a method for preparing pranoprofen. The present invention further relates to a composition containing pranoprofen and an impurity, a quality control method, and an int...
|
|
WO/2022/272154A2 |
Disclosed herein are pharmaceutical compositions comprising biosynthetic allosteric mTOR inhibitors that can have improved pharmacology and reduced toxicity. Also disclosed herein are methods of treating a condition or disease by adminis...
|
|
WO/2022/270592A1 |
This compound represented by a general formula is useful as an electron barrier material. R1 through R5 are a deuterium atom, a substituent other than a cyano group; n1, n3, n5 are 0-4; n2 is 0-3; n4 is 0-2; X is O or S; and Ar is a mono...
|
|
WO/2022/269508A1 |
The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compo...
|
|
WO/2022/268026A1 |
The present invention relates to 1,2,4-triazole compounds as AXL inhibitors. These compounds are suitable for treating or preventing AXL receptor tyrosine kinase-induced diseases.
|
|
WO/2022/267495A1 |
The present invention relates to a nitrogen-containing oxa-spirocyclic compound and the use thereof, and in particular relates to the compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof as an LSD1 in...
|
|
WO/2022/272020A1 |
Provided herein are compounds of formula (I): (I) and pharmaceutically-acceptable salts thereof, where A, W, X, Y and Z are defined in the specification. The compounds of formula (I) and pharmaceutically-acceptable salts thereof are Janu...
|
|
WO/2022/270741A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting device, and a composition for an organic material layer of an organic light-emitting device.
|
|
WO/2022/271749A1 |
The present disclosure provides a compound represented by structural formula (I):or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/268890A1 |
The present invention provides compounds of the general formula (I) or a pharmaceutically acceptable prodrugs, salts and/or solvates thereof, wherein LHS is formula (II). And wherein, the asterisk (*) marks the point of attachment; These...
|
|
WO/2022/267839A1 |
The present application relates to the technical field of organic materials, and specifically relates to an organic compound, an electronic component, and an electronic device. The organic compound having a structure represented by formu...
|
|
WO/2022/266363A1 |
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibit...
|
|
WO/2022/262789A1 |
An antitumor compound and the use thereof. Specifically, the present invention relates to a ligand conjugate or a tautomer, a mesomer, a racemate, an enantiomer and a diastereomer thereof, or a mixture thereof, or a pharmaceutically acce...
|
|
WO/2022/262615A1 |
The present invention relates to an anthracene compound of formula A, a preparation method therefor, and a medical use thereof. The anthracene compound has the effect of inhibiting the growth of tumor cells, and has the potential as an a...
|
|
WO/2022/261770A1 |
The present invention relates to a combination comprising a neurotensin receptor binding compound and FOLFIRINOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
|
|
WO/2022/266236A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2022/261473A1 |
The application relates to compounds of Formula (I) and (III), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory sy...
|
|
WO/2022/261204A1 |
Disclosed are compounds of formula (I): formula (I) and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII- selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute k...
|
|
WO/2022/256284A1 |
Disclosed are compounds of Formula (I), including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R3, A and T are as defined in the disclosure. Also disclosed are compositions containing the compounds of For...
|
|
WO/2022/256702A1 |
Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and m...
|
|
WO/2022/256299A1 |
The present invention relates to compounds of formula (I) that are inhibitors of PlKfyve kinase and are therefore useful for the treatment of e.g. neurological diseases, such as e.g. amyotrophic lateral sclerosis (ALS), Parkinson's disea...
|
|
WO/2022/253327A1 |
Disclosed are a preparation method and use of a compound having an immunomodulatory function. Specifically, disclosed is a compound having the structure as shown in formula I, wherein the definition of each group is as described in the s...
|
|
WO/2022/216971A9 |
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
|
|
WO/2022/256679A1 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and...
|
|
WO/2022/256676A1 |
Compounds of formula I, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and ...
|
|
WO/2022/253252A1 |
Disclosed herein are compounds of Formula (I) : or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase (HPK1), and...
|
|
WO/2022/247641A1 |
Provided are a new class of compounds having a WEE1 inhibitory effect and as represented by formula I, and the use thereof in the preparation of a drug.
|
|
WO/2022/251482A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2022/247772A1 |
Disclosed are crystal forms of an oxygen-containing heterocyclic compound, a preparation method therefor and an application thereof. The crystal forms include a crystal form A of a compound represented by formula (I), a crystal form B of...
|
|
WO/2022/250224A1 |
The present invention relates to a PROTAC compound which can increase the degradation effect of a protein of interest, and to a novel piperidinedione compound which can be used as an E3 enzyme ligand of the PROTAC compound. The piperazin...
|
|
WO/2022/249505A1 |
A compound represented by the general formula herein is an excellent light-emitting material. R1 to R5 each represent a hydrogen atom, a deuterium atom, or a substituent other than a cyano group, with at least one among R1 to R5 being an...
|
|
WO/2022/251576A1 |
Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosur...
|
|
WO/2022/246576A1 |
Camptothecin analogues of Formula (I) and conjugates comprising the camptothecin analogues are described. The camptothecin analogues and conjugates may be used as therapeutic agents, particularly in the treatment of cancer, an autoimmune...
|
|
WO/2022/249506A1 |
A compound represented by the general formula herein is an excellent light-emitting material. R1 to R5 each represent a hydrogen atom, a deuterium atom, or a substituent other than a cyano group, with at least one among R1 to R5 being an...
|
|
WO/2022/246109A1 |
Provided herein are compounds of Formula (I): wherein the various substituents are defined herein.
|
|
WO/2022/241077A1 |
Described herein is a therapeutic method that specifically addresses tumor-infiltrated regulatory T cells (Tregs) with minimal impact on the peripheral Tregs. In certain aspects, the invention provides a method of treating, preventing, o...
|
|
WO/2022/238327A1 |
The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compound...
|
|
WO/2022/238335A1 |
The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for...
|
|
WO/2022/237676A1 |
Disclosed in the present invention are a SHP2 phosphatase inhibitor and an application thereof. Specifically, the present invention relates to a compound as represented by formula (I), a preparation method therefor, a pharmaceutical comp...
|
|
WO/2022/238579A1 |
The present invention relates to novel compounds of Formula (I), wherein A, m, Q, R1, R2, R3, R4 and R5 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and ...
|
